1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

GW PHARMA’S HOPES COULD STILL GO UP IN SM

By Alfa, Jun 24, 2005 | |
  1. Alfa
    GW PHARMA'S HOPES COULD STILL GO UP IN SMOKE


    While multiple sclerosis sufferers have long argued that smoking cannabis relieves their muscle problems and chronic pain, it has taken GW Pharmaceuticals to develop the world's first medicine based on cannabis and available on prescription for MS patients.


    The drug is Sativex, an under-the-tongue spray, and it was launched yesterday as a pain medicine for MS in Canada. This is a monumental achievement for a UK drug company and it speaks highly of the company's scientific nous and the chutzpah of its founder, Geoffrey Guy.


    But it is not a reason to invest in GW's shares. It is having a much harder time getting Sativex approved in the UK, where the regulator has been more sceptical of its claims to relieve spacticity. Go back and do more work, GW was told.


    That work is costly. Losses were pared to UKP 5.1m in the first six months of the year, but the company is still burning through more than UKP 1m a month and knows that regulators are demanding bigger and more statistically significant trials if Sativex is to get on the market in Europe. Although there will be some money coming in from Canadian sales, the company's UKP 16.2m cash pile will be whittled away by the end of next year.


    Encumbered with a history of over-optimism, the company knows it will not be able to raise cash from shareholders at the current price. So it is hoping instead to sell marketing rights to Sativex in continental Europe as it has done in the UK and Canada. Unless Canadian sales turn out to be spectacular (unlikely in a country which already allows MS sufferers to smoke cannabis), these deals might not bring in enough. Avoid.

Comments

To make a comment simply sign up and become a member!